QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kopin

Novavax

Unum Therapeutics

Veritone

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside

D.R. Horton

PulteGroup

PerkinElmer

West Pharmaceutical Services

A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.

Wall Street is Northbound Defying All Concerns: 5 Top Picks

Two very different companies with two very promising COVID-19 programs.

Better Coronavirus Stock: Novavax vs. Quidel

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has entered into a preliminary letter contract with the National Institutes of Health (NIH) through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms (RADx-ATP) initiative to support the expansion of its manufacturing capacity in San Diego for its

Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19

Quidel Corporation (QDEL) CEO Peter Ingram on Q2 2020 Results - Earnings Call Transcript

Quidel (QDEL) delivered earnings and revenue surprises of 66.07% and 0.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Quidel (QDEL) Surpasses Q2 Earnings and Revenue Estimates

Quidel late Thursday reported earnings and sales well ahead of expectations, and shares of the coronavirus test company rose in after-hours trading, after rising 4.3% in the regular session.
The post Coronavirus Test Company Quidel Passes Earnings Test; Stock Rises appeared first on Investor's Business Daily.

Coronavirus Test Company Quidel Passes Earnings Test; Stock Rises

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2020. Second Quarter 2020 Highlights Total revenue increased 86% to $201.8 million, from $108.3 million in the second quarter of 2019.

Quidel Reports Second Quarter 2020 Financial Results

SAN DIEGO--(BUSINESS WIRE)--In the first paragraph, the date of the conference should read: Thursday, August 13, 2020 (instead of Wednesday, August 13, 2020). The corrected release reads: QUIDEL TO PRESENT VIRTUALLY AT THE CANACCORD GENUITY 40th ANNUAL GROWTH CONFERENCE Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Canaccord Genuity 40th Annual Grow

CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Canaccord Genuity 40th Annual Growth Conference, to be held virtually on Wednesday, August 13, 2020. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 10:30 a.m.

Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference

Baxter

Bio-Rad Laboratories

Stryker

Teleflex

Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.

Medical Products Stock Earnings on Jul 30: BAX, SYK & More

Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth

SAN DIEGO--(BUSINESS WIRE)--Elizabeth Lee-Lewandrowski, Ph.D., MPH, to discuss findings of a national seven-year study on Lyme disease testing on a webinar on Thursday, July 30.

Published National Findings in Lyme Disease Testing to Be Discussed on July 30 Webinar Hosted by Quidel Corporation

Veeva Systems

Zoom Video

Now might be a good time to sell these stocks, before their bubbles burst.

These 3 Stocks Near All-Time Highs Will Be Dangerous When the Next Crash Comes

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has updated the performance data for its Sofia® SARS Antigen FIA test on its package insert to 96.7% using direct nasal swab specimens versus PCR as a result of further studies included in its amended Emergency Use Authorization (EUA) that were submitted to the U.S. Food and Drug A

Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 Instruments

The company's leadership in COVID-19 antigen testing is earning it lot of attention, and more is sure to come.

Why Is Everyone Talking About Quidel Stock?

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Distribution of rapid point-of-care diagnostic instruments from Quidel and Becton, Dickinson will begin next week.

Federal Government to Send Millions of COVID-19 Tests to Nursing Homes

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report second fiscal quarter 2020 financial results after market close on Thursday, July 30, 2020. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Tim

Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020

Corcept Therapeutics

Vertex Pharmaceuticals

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks

Shares of the maker of rapid COVID-19 tests continued their upward movement last month.

Why Quidel Stock Rose 28% in June

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the second fiscal quarter of 2020 to be in the range of $201 million to $202 million, an increase of approximately 86% - 87% over the prior year quarter. “Our second quarter was even stronger than we had expected, driven by demand for our COVID-19 Molecular Diagnost

Quidel Announces Preliminary Revenue for Second Quarter 2020

Point-of-care diagnostics are more popular than ever, and Quidel's driving the trend.

Should Quidel Be Your Next Coronavirus Buy?

Quidel: Prescribed But Only At The Right Dose

Quidel (QDEL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Quidel (QDEL) Catches Eye: Stock Jumps 6.3%

B&G Foods

Fortinet

Vistra Energy

Investing in stocks from defensive sectors like utilities, healthcare and consumer staples and remote working can prove prudent in the current market scenario.

News for QuidelOrtho Corp Stock (QDEL)